Improving Clinical Reality in Chronic Obstructive Pulmonary Disease Economic Modelling

[1]  W. Bailey,et al.  Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution , 2023, Medical science monitor : international medical journal of experimental and clinical research.

[2]  R. Holle,et al.  A Lifetime Markov Model for the Economic Evaluation of Chronic Obstructive Pulmonary Disease , 2012, PharmacoEconomics.

[3]  M. R. Rutten-van Mölken,et al.  Cost Effectiveness of Pharmacological Maintenance Treatment for Chronic Obstructive Pulmonary Disease , 2012, PharmacoEconomics.

[4]  M. Hoogendoorn.  Economic impact of COPD: Empirical and model-based studies on the cost-effectiveness of treatment options , 2011 .

[5]  A. Briggs,et al.  Predicting EQ-5D values using the SGRQ. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[6]  G A Whitmore,et al.  A threshold regression model for recurrent exacerbations in chronic obstructive pulmonary disease. , 2010, Journal of clinical epidemiology.

[7]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[8]  M. Neyt,et al.  Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions , 2010, BMC pulmonary medicine.

[9]  J. Lötvall,et al.  Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. , 2010, American journal of respiratory and critical care medicine.

[10]  H. Magnussen,et al.  Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD , 2010, Thorax.

[11]  G. Feldman,et al.  Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study , 2010, BMC pulmonary medicine.

[12]  Niels H Chavannes,et al.  Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. , 2009, American journal of respiratory and critical care medicine.

[13]  A. Lindberg,et al.  A 20-Year Follow-Up of a Population Study-Based COPD Cohort-Report from the Obstructive Lung Disease in Northern Sweden Studies , 2009, COPD.

[14]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[15]  V. Entwistle,et al.  The information and support needs of patients discharged after a short hospital stay for treatment of low-risk Community Acquired Pneumonia: implications for treatment without admission , 2008, BMC pulmonary medicine.

[16]  A. Briggs,et al.  Pharmacoeconomics in COPD: lessons for the future , 2008, International journal of chronic obstructive pulmonary disease.

[17]  M. Aalabaf-Sabaghi.  Decision modelling for health economic evaluation , 2007, Journal of Epidemiology and Community Health.

[18]  M. Miravitlles,et al.  Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain , 2007, The European Journal of Health Economics.

[19]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[20]  S. Chick,et al.  A taxonomy of model structures for economic evaluation of health technologies. , 2006, Health economics.

[21]  A. Buist,et al.  A dynamic population model of disease progression in COPD , 2005, European Respiratory Journal.

[22]  Philip Jacobs,et al.  Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. , 2004, The American journal of medicine.

[23]  Sean D Sullivan,et al.  A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[24]  S. Hurd,et al.  Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update , 2003, European Respiratory Journal.

[25]  W. Bailey,et al.  Smoking Cessation and Lung Function in Mild-to-Moderate Chronic Obstructive Pulmonary Disease , 2000 .

[26]  S. Ramsey,et al.  The economic burden of COPD. , 2000, Chest.

[27]  M J Buxton,et al.  Modelling in economic evaluation: an unavoidable fact of life. , 1997, Health economics.

[28]  Humphrey D L Birley,et al.  Implicit memory , 1994, BMJ.

[29]  A. Buist,et al.  The Lung Health Study. Baseline characteristics of randomized participants. , 1993, Chest.

[30]  P. Jones,et al.  The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.

[31]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[32]  C. Wells,et al.  The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. , 1984, Chest.

[33]  A. Cournand,et al.  Relation of the Regulatory Mechanism of Respiration to Clinical Dyspnea. , 1935, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration , 2013 .

[35]  A. Briggs,et al.  Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease , 2012, PharmacoEconomics.

[36]  E. Lydick,et al.  A New Method for Examining the Cost Savings of Reducing COPD Exacerbations , 2012, PharmacoEconomics.

[37]  S. Hurd,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[38]  J.,et al.  Markov Models in Medical Decision Making : A Practical Guide , 2006 .

[39]  Jan B Oostenbrink,et al.  Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[40]  D. Forman,et al.  Delays in managing lung cancer. , 2004, Thorax.

[41]  W. Bailey,et al.  Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. , 2000, American journal of respiratory and critical care medicine.